COPD trials in Slovakia
5 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleA Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis
- Where
- Banska Bystrica, Bardejov, Košice, Levice, Spišská Nová Ves
- Age
- 40 years to 80 years
- People
- 402 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT07725939 · EU 2026-525523-25-00 - Phase 3Taking peopleEfficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- Where
- Humenné, Levice, Spišská Nová Ves
- Age
- 40 years to 80 years
- People
- 942 worldwide
- Run by
- Sanofi
See details and how to joinNCT07190222 · EU 2024-518213-25-00 - Phase 3Taking peopleDepemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
- Where
- Humenne, Kosice, Spišská Nová Ves
- Age
- 40 years to 80 years
- People
- 981 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT06959095 · EU 2024-520418-22-00 - Phase 3Taking peopleA Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Where
- Bardejov, Bratislava, Brezno, Humenne, Košice, Kráľovský Chlmec, Levice, Topoľčany
- Age
- 40 years to 80 years
- People
- 5,250 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06283966 · EU 2023-507407-59-00 - Phase 3Taking peopleA Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
- Where
- Humenne, Kosice, Levice
- Age
- 40 years to 80 years
- People
- 990 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06883305 · EU 2024-517458-90-00